I Iune 29, 2017,ʻo ka hoʻomohalaʻana o Laulututa, ka papa mīkini haʻo wau i ka hoʻomohalaʻana i kaʻenehana kūloheloheʻo JYMEDHOATH. Uaʻaeʻia ka hoʻolahaʻana o ka lāʻau lapaʻau i ka lāʻau lapaʻau e ka CFDA.

ʻO Jymemed a me Guangzhou Lintheath Medical Technology Coffic Cools Co., Ltd. A hiki i kahi kuʻikahi hui i ka makahiki 2016 e hoʻomohala i kēia huahana ma Kina. Ua hoʻopau nāʻano i nā haʻawina pc Hiki ke nānāʻia ka FDA a me ka EMA i kēia mauʻano hana no ka mālamaʻana i ka mea maʻi a me ka hoʻomaʻamaʻaʻana i nā mea maʻi.

ʻO nā colitis Ulcerative (UC) he maʻi maʻi, non-sticlimmator maʻi e hele ana i loko o ka rectum a me nā colle. Wahi a nā helu helu,ʻo ka helu hanana o UC he 1.2 a 20.3 i nā hihia o ka uc a me nā hihia he 246.0. ʻO ka hopena o UC ka mea maʻamau i nā'ōpio'ōpio. Nui ka mākeke UC a he kumu nui no nā lāʻau lapaʻau, a hoʻomau mau e mālama i kahi ulu ulu kiʻekiʻe i ka wā e hiki mai ana. Ma kēia manawa,ʻo UC mua ka lāʻau lapaʻau mua e pili ana i ka mesalazine a me nā hormones a me nā mea kanu lua a me nā mea kanu monoclonsupressies a me nā mea hoʻonaninani ʻO Mesalazine kahi helu kūʻai o ka 1 biliona ma Kina a me US $ 2 Billion iʻAmelika Hui PūʻIa ma 2015. Loaʻa iā ia kahi hana maikaʻi maikaʻi a manaʻoʻia e lilo i ka lāʻau lapaʻau mua o UC.